July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Investigating the effect of the anti-inflammatory agent minocyline on Wnt-induced retinal ganglion cell survival and axonal regeneration.
Author Affiliations & Notes
  • Sarah Marie Gough
    Bascom Palmer Eye Institute , University of Miami Miller School of Medicine , Miami, Florida, United States
  • Adanna Udeh
    Bascom Palmer Eye Institute , University of Miami Miller School of Medicine , Miami, Florida, United States
  • Tal Carmy
    Bascom Palmer Eye Institute , University of Miami Miller School of Medicine , Miami, Florida, United States
  • Kevin Park
    Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, Miami, Florida, United States
  • Abigail Hackam
    Bascom Palmer Eye Institute , University of Miami Miller School of Medicine , Miami, Florida, United States
  • Footnotes
    Commercial Relationships   Sarah Gough, None; Adanna Udeh, None; Tal Carmy, None; Kevin Park, None; Abigail Hackam, None
  • Footnotes
    Support  NEI RO1 EY026546, NEI P30 EY014801
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 4853. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sarah Marie Gough, Adanna Udeh, Tal Carmy, Kevin Park, Abigail Hackam; Investigating the effect of the anti-inflammatory agent minocyline on Wnt-induced retinal ganglion cell survival and axonal regeneration.. Invest. Ophthalmol. Vis. Sci. 2019;60(9):4853.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Optic neuropathies are characterized by damage to axons of the optic nerve resulting in visual impairments. We previously showed that activation of the Wingless-type (Wnt) signaling pathway using Wnt3a ligand promoted retinal ganglion cell (RGC) survival and axonal regeneration after optic nerve crush (ONC) in mice. Interestingly, Wnt3a-injected retinas showed significantly more microglia/macrophages, suggesting a role for inflammation in Wnt3a-induced axonal regeneration. In this study, we investigated how inflammation contributes to Wnt3a-mediated axonal regeneration and RGC neuroprotection.

Methods : Mice were injected with Wnt3a (20 ng) or saline intravitreally then immediately underwent ONC injury. Mice received IP injections of the anti-inflammatory agent minocycline (45 mg/kg) or water on the day of ONC, then three times a week for 2.5 weeks. Immunohistochemistry on retinal sections and flatmounts was used to detect RBPMS for quantification of RGCs. Axonal regeneration was measured using cholera toxin B injection, quantifying the number of axons at 100 um intervals past the crush site.

Results : Intravitreal injections of Wnt3a resulted in significant axonal regrowth past the lesion site and increased RGC survival compared with saline controls (n=4-6, p<0.05). Wnt3a-injected mice treated with minocycline had equivalent axonal growth as Wnt3a-injected mice without minocycline (n=6-9, two-way ANOVA). In contrast, in the absence of Wnt3a (saline control), minocycline induced significantly more axons growing past the lesion site compared with saline injected mice without minocycline (p=0.026, n=5-9, two-way ANOVA). Furthermore, minocycline eliminated the neuroprotective effect of Wnt3a (n=5, ANOVA).

Conclusions : These data demonstrate that inflammation is a double-edge sword after ONC, which inhibits basal regeneration but promotes RGC survival. Wnt3a was able to overcome the inhibitory effect of inflammation on axon growth but not RGC survival. Therefore, these results increase our understanding of the role of inflammation in optic nerve regeneration.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×